Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension

doi:10.3748/wjg.v24.i38.4356

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 38

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6442)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

477

HTML

3460

Figures (1-3)

170

Tables (1-6)

174

Sum=4281

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

938

Download

1223

Sum=2161

Oct 14, 2018 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Oct 14, 2018; 24(38): 4356-4368
Published online Oct 14, 2018. doi: 10.3748/wjg.v24.i38.4356

Full Size Figure Download Figure

Figure 2 Immunohistochemical localization of phosphodiesterase-5. A-C: Healthy liver; D-F: Cirrhotic liver. Red arrows: Localization in zone 3 hepatocytes; Blue arrows: Localization in perisinusoidal cells; Green Arrow: Fibrous septa.

Citation: Schaffner D, Lazaro A, Deibert P, Hasselblatt P, Stoll P, Fauth L, Baumstark MW, Merfort I, Schmitt-Graeff A, Kreisel W. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension. World J Gastroenterol 2018; 24(38): 4356-4368
URL: https://www.wjgnet.com/1007-9327/full/v24/i38/4356.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i38.4356